Variant
ROS1 S1986Y/F
CI-VAR-00004018Explore in graph →CIViC 2856
Curated evidence
Evidence by cancer (1 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 27401242
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Lung Non-Small Cell Carcinoma1 | ||||||||
| ROS1 S1986Y/F | Lorlatinib | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID7689A patient with ROS1 fusion-positive NSCLC was treated with crizotinib and led to durable response (-75%) over 22 months. After tumor progression, a rebiopsy sample was obtained and revealed ROS1 S1986… (full text at CIViC) PMID 27401242 · Facchinetti et al., 2016 · Open in CIViC | civic |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available
No ClinVar interpretation attached to this variant.